The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat

Journal of Urology

Volumn 161, Issue 5, 1999, Pages 1707-1712

  Andersson, Karl Erik ^b   Gemalmaz, Hakan ^b   Waldeck, Kristian ^b   Chapman, Terence N ^b   Tuttle, Jeremy B ^b   Steers, William D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

Dopamine; Erection; Impotence; Phosphodiesterase; Sexual function

Indexed keywords

APOMORPHINE; SILDENAFIL;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ERECTILE DYSFUNCTION; IMPOTENCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE TRANSECTION; NONHUMAN; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PUDENDAL NERVE; RAT;

EID: 0032876253     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)69009-X     Document Type: Article

References (30)

1. de Groat, W. C. and Steers, W. D.: Neuroanatomy and neurophysiology of penile erection. In: Contemporary Management of Impotence and Infertility. Edited by E. A. Tanagho, T. F. Lue, and R. D. McClure. Baltimore: Williams & Wilkins, pp. 3-27, 1988.
2. de Groat, W. C. and Booth, A. M.: Neural control of penile erection. In: The Autonomic Nervous System. Vol. 6, Chapter 13, nervous control of the urogenital system. Edited by C. A. Maggi. London: Harwood Academic Publishers, pp. 465-513, 1993.
3. Andersson, K-E. and Wagner, G.: Physiology of penile erection. Physiol. Rev., 75: 191, 1995.
4. Mogilnika, E. and Klimek, V.: Drugs affecting dopamine neurons and yawning behavior. Pharmacol. Biochem. Behav., 31: 303, 1977.
5. Benassi-Benelli, A., Ferrari, F. and Pellegrini Quarrantotti, B.: Penile erection induced by apomorphine and N-n-propylnorapomorphine in rats. Arch. Int. Pharmacodyn., 242: 241, 1979.
6. Serra, G., Collu, M., Loddo, A., Celasco, G. and Gessa, G. L.: Hypophysectomy prevents yawning and penile erection but not hypomotility induced by apomorphine. Pharmacol. Biochem. Behav., 19: 917, 1983.
7. Gower, A. J., Berendsen, H. H. G., Princen, M. M. and Broekkamp, C. L. E.: The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur. J. Pharmacol., 103: 81, 1984.
8. Melis, A., Argiolas, A. and Gessa, G. L.: Apomorphine-induced penile erection and yawning: site of action in brain. Brain Res., 415: 98, 1987.
9. Boolell, M., Allen, M., Ballard, S., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Osterloh, I. H. and Gingell, C.: Sildenafil: an orally active type 5 cyclic CMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impotence Res., 8: 47, 1996.
10. Buvat, J. and the Multicenter Study Group: Sildenafil (viagra), an oral treatment for erectile dysfunction; a 1-year, open-label, extension study. J. Urol., 157: 204 (abstract 793), 1997.
11. Lue, T. F. and the Sildenafil Study Group: A study of sildenafil (viagra), a new oral agent for the treatment of male erectile dysfunction. J. Urol., 157: 181 (abstract 701), 1997.
12. Steers, W. D. and the Sildenafil Study Group: Sildenafil (viagra) is effective in the treatment of severe male erectile dysfunction. 2nd Meeting of the European Society for Impotence Research, October 1-4, abstract 55, 1997.
13. Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D. and Wicker, P. A.: Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med., 338: 1397, 1998.
14. Heaton, J. P. W., Varrin, S. J. and Morales, A.: The characterization of a bioassay of erectile function in a rat model. J. Urol., 145: 1099, 1991.
15. Paick, J-S. and Lee, S. E.: The neural mechanism of apomorphine-induced erection: an experimental study by comparison with electrostimulation-induced erection in the rat model. J. Urol., 152: 2125, 1994.
16. Bitran, D. and Hull, E. M.: Pharmacological analysis of male rat sexual behavior. Neurosci. Biobehav. Rev., 11: 365, 1987.
17. Foreman, M. M. and Hall, J. L.: Effects of D2 dopaminergic receptor stimulation on male rat sexual behavior. J. Neural Transm., 68: 153, 1987.
18. Butcher, L. L., Butcher, S. G. and Larsson, K.: Effects of apomorphine, (+)-amphetamine, and nialamide on tetrabenazine-induced suppression of sexual behavior in the male rat. Eur. J. Pharmacol., 7: 283, 1969.
19. Martinez-Pineiro, L., Brock, G., Trigo-Rocha, F., Hsu, G. L., Lue, T. F. and Tanagho, E. A.: Rat model for the study of penile erection: pharmacologic and electrical-stimulation parameters. Eur. Urol., 25: 62, 1994.
20. Gemalmaz, H., Waldeck, K., Chapman, T. N., Tuttle, J. B., Steers, W. D. and Andersson, K-E.: Sildenafil/viagra enhances apomorphine-induced intracavernous pressure in awake rats. J. Urol., 149: 91 (suppl.), 1990.
21. Pehek, E. A., Thompson, J. T., Eaton, R. C. and Hull, E. M.: Apomorphine and haloperidol, but not domperidone, affect penile responses in rats. Pharmacol. Biochem. Behav., 31: 201, 1988.
22. Argiolas, A. and Melis, M. R.: Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Progr. Neurobiol., 47: 235, 1995.
23. Boolell, M., Gepi-Attee, S., Gingell, J. C. and Allen, M. J.: Sildenafil, a novel oral therapy for male erectile dysfunction. Br. J. Urol., 78: 257, 1996.
24. Ballard, S. A., Gingell, C. J., Tang, K., Turner, L. A., Price, M. E. and Naylor, A. M.: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol., 159: 2164, 1998.
25. Tang, K., Turner, L. A., Ballard, S. A. and Naylor, A. M.: Effects of a novel phosphodiesterase type 5 inhibitor, sildenafil, on methacholine induced relaxation of isolated rabbit corpus cavernosum (abstr). Br. J. Pharmacol., 118: 154P, 1996.
26. Ballard, S. A., Turner, L. A. and Naylor, A. M.: Sildenafil, a potent selective inhibitor of type 5 phosphodiesterase enhances nitric oxide-dependent relaxation of rabbit corpus cavernosum (abstr). Br. J. Pharmacol., 118: 153P, 1996.
27. Chuang, A. T., Strauss, J. D., Murphy, R. A. and Steers, W. D.: Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J. Urol., 160: 257, 1998.
28. Stief, C. G., Uckert, S., Becker, A. J., Truss, M. C. and Jonas, U.: The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J. Urol., 159: 1390, 1998.
29. Carter, A. J., Ballard, S. A. and Naylor, A. M.: Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog. J. Urol., 160: 242, 1998.
30. Jeremy, J. Y., Ballard, S. A., Naylor, A. M., Miller, M. A. W. and Angelini, G. D.: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol., 79: 958, 1997.